<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065398</url>
  </required_header>
  <id_info>
    <org_study_id>HLX208-NSCLC201</org_study_id>
    <nct_id>NCT05065398</nct_id>
  </id_info>
  <brief_title>A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation</brief_title>
  <official_title>An Open Label， Multicenter Phase II Clinical Trial to Evaluate the Efficacy，Safety and Pharmacokinetics of HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy，safety and pharmacokinetics of HLX208 in advanced non-small cell lung&#xD;
      cancer patients with BRAF V600 mutation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>from first dose to the last patient was followed up for 6 month</time_frame>
    <description>The number of patients with CR or PR divided by the total number of treated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>the time (month is regarded as the unit) from the first dose to the date of first documented progression or date of death from any cause, whichever came first,through treatment completion, an average of about 1 year</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>from the first occurrence of a documented CR or PR (whichever recorded earlier) to the time of first documented disease progression or death (whichever occurs first),through treatment completion, an average of about 1 year</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from the first dose to the time of death due to any cause, an average of about 2 year</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>HLX208</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX208</intervention_name>
    <description>450mg bid, take orally</description>
    <arm_group_label>HLX208</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;=18Y&#xD;
&#xD;
          -  Good Organ Function&#xD;
&#xD;
          -  Expected survival time ≥ 3 months&#xD;
&#xD;
          -  advanced BRAF V600 NSCLC that have been diagnosed histologically or cytology and have&#xD;
             failed standard treatment or unable to receive, or refusing standard care.&#xD;
&#xD;
          -  Previous failure to standard treatment, or insuitability for standard treatment or&#xD;
             refuse standard treatment.&#xD;
&#xD;
          -  ECOG score 0-2;&#xD;
&#xD;
          -  Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with BRAF inhibitors or MEK inhibitors&#xD;
&#xD;
          -  Presence of EGFR mutations or ALK rearrangements (unless disease progression following&#xD;
             prior treatment with tyrosine kinase inhibitors).&#xD;
&#xD;
          -  Symptomatic brain or meningeal metastases (unless the patient has been on &gt; treatment&#xD;
             for 1 months, has no evidence of progress on imaging within 4 weeks prior to initial&#xD;
             administration, and tumor-related clinical symptoms are stable).&#xD;
&#xD;
          -  Current or former patients with interstitial lung disease;&#xD;
&#xD;
          -  Severe active infections requiring systemic anti-infective therapy&#xD;
&#xD;
          -  A history of other malignancies within two years, except for cured cervical carcinoma&#xD;
             in situ, basal cell carcinoma of the skin, adenocarcinoma in situ of the lung, or&#xD;
             tumors that do not require interventional treatment after radical surgery.&#xD;
&#xD;
          -  Other anti-tumor treatments, such as chemotherapy, targeted therapy, or radiation&#xD;
             therapy (except palliative radiation therapy), may be given during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

